Cargando…

Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo

Isomerisation to all-trans-retinoic acid (ATRA) is widely accepted as the key mechanism underlying the favourable clinical properties of 13-cis-retinoic acid (13cisRA). As intracellular metabolism of ATRA by CYP26 may result in clinical resistance to 13cisRA, an increase in efficacy may be achieved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, J L, Taylor, G A, Thomas, H D, Boddy, A V, Redfern, C P F, Veal, G J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359919/ https://www.ncbi.nlm.nih.gov/pubmed/17486130 http://dx.doi.org/10.1038/sj.bjc.6603779

Ejemplares similares

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
por: Armstrong, J L, et al.
Publicado: (2005)

Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity
por: Van heusden, J, et al.
Publicado: (2002)

ATP7A is a novel target of retinoic acid receptor β(2) in neuroblastoma cells
por: Bohlken, A, et al.
Publicado: (2009)

In vivo effects of rosiglitazone in a human neuroblastoma xenograft
por: Cellai, I, et al.
Publicado: (2010)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006)

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells
por: Valenzuela, M, et al.
Publicado: (2014)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3
por: Patel, S A A, et al.
Publicado: (2014)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Hexokinase 2 is a determinant of neuroblastoma metastasis
por: Edry Botzer, Liat, et al.
Publicado: (2016)

Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57
por: Corazzari, M, et al.
Publicado: (2007)

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
por: Ryan, J, et al.
Publicado: (2012)

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
por: Pasquier, E, et al.
Publicado: (2013)

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
por: Blaheta, R A, et al.
Publicado: (2007)

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
por: Martinez, V G, et al.
Publicado: (2008)

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
por: Lamont, F R, et al.
Publicado: (2011)

Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model
por: Chiu, B, et al.
Publicado: (2014)

Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-γ
por: Ribatti, D, et al.
Publicado: (2006)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
por: Daniel, R A, et al.
Publicado: (2010)

Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R
por: Gravells, P, et al.
Publicado: (2011)

Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice
por: Huynh, C K, et al.
Publicado: (2006)

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
por: Pridgeon, S W, et al.
Publicado: (2011)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

N-(4-iodophenyl)-N′-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice
por: Borel, M, et al.
Publicado: (2007)

Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor
por: Jamieson, D, et al.
Publicado: (2006)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation
por: Ash, S, et al.
Publicado: (2010)

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
por: Yamamoto, J, et al.
Publicado: (2014)

Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
por: Theys, J, et al.
Publicado: (2006)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects
por: Ferreira, A K, et al.
Publicado: (2013)

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo
por: Bright, S A, et al.
Publicado: (2010)

The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
por: Quintela-Fandino, M, et al.
Publicado: (2013)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells
por: Frame, F M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_avjifungt52rj5h90ln0r02526